The Work-Up: Costly Drugs Known as Biologics Prompt Exclusivity Debate

Tuesday, July 21, 2009 - 23:35 in Psychology & Sociology

Companies that own the rights to high-end treatments say allowing copycats to market too soon would hurt financial incentives.

Read the whole article on NY Times Health

More from NY Times Health

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net